HCPCS J9332 is officially defined as "Injection, efgartigimod alfa-fcab, 2mg." HCPCS J9332 is referenced in 22 tracked payer policy changes from Sentara Health Plans, Independence Blue Cross, and 7 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9332 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Starting January 1, 2027, Sentara Health Plans will require prior authorization for a long list of codes on Virginia commercial plans, including self-funded (ASO) plans, and for code 88380 on commercial, Medicaid and Medicare products, plus code 22860 on Medicare products. Sentara will also stop covering a separate list of codes on Virginia commercial and self-funded plans.
Independence Blue Cross Medicare Advantage policy MA08.142f adds new contraindication restrictions for efgartigimod alfa-fcab (Vyvgart) effective 10/26/2026, prohibiting concurrent use with FcRn blockers, complement inhibitors, immune globulin, and requiring neurologist involvement. The policy also removes the previous AChR antibody-positive requirement for gMG coverage. Billing teams must update prior authorization rules and clinical criteria checks before the October effective date.
Florida Blue Medicare has updated its Part B Step Therapy program effective October 1, 2026, restructuring preferred and non-preferred medication classifications across six drug categories (Autoimmune Therapy, Bone Remodeling Agents, Cancer and Supportive Therapy, Colony-Stimulating Factors, Complement Inhibitors, and Ophthalmic Agents). Billing teams must verify that prescriptions align with updated preferred product lists and implement prior authorization requirements for non-preferred medications to prevent claim denials.
BlueCare Tennessee has implemented new step therapy requirements for provider-administered specialty drugs effective July 1, 2026. Providers must try preferred alternative medications before using requested specialty drugs across multiple therapeutic categories including autoimmune conditions, oncology, growth factors, and more.
Premera HMO plans in Washington have changes from the October 2025 medical policy and coding update. Dated items include the Abdominal Wall Hernia policy and its codes effective January 2, 2026, advanced imaging site-of-care review through Carelon and a Washington mandate for medical clearance of minors' hearing aid coverage effective January 1, 2026, and Federal Employee Program prior authorization for hip, knee and spine surgery effective January 1, 2026. Several biologic and drug policies also moved products between preferred and non-preferred status.
Premera HMO plans in Washington have changes from the September 2025 medical policy and coding update. The lead item is advanced imaging site-of-care review through Carelon Medical Benefits Management, Inc., effective January 1, 2026 for dates of service on and after that date. Many coded services also now require review for medical necessity and prior authorization, including negative pressure wound therapy, oncology drugs, percutaneous coronary intervention and selected ASC surgical procedures.
Florida Blue Medicare updated its Part B Step Therapy programs for Medicare Advantage plans, effective January 1, 2026. Multiple drug categories now have new preferred and non-preferred medications, requiring step therapy trials of preferred products before non-preferred drugs can be approved.
BlueCross BlueShield of Tennessee's upcoming step therapy guide for Commercial and BlueCare Plus Tennessee lists provider administered specialty drugs that need a preferred alternative tried first, including biosimilars, infused biologics, bevacizumab, botulinum toxins, hyaluronic acid injections, growth factor products and rituximab and trastuzumab products. The practice needs to check upcoming infused and injected drugs against this list and document the indication, dose, frequency and duration so requests and exceptions match the policy.
Effective October 3, 2025, codes for several drugs, including J0491, J0517, J0638, J2182, J2351, J2356, J2357, J3032, J3111, J3241, J9024, J9272, J9332 and J9334, now require review for site of service, in addition to the existing medical necessity and prior authorization review. Physical and occupational therapy services for individual plans require prior authorization starting with the seventh visit, effective July 3, 2025. Effective September 5, 2025, non-individual plans use InterQual criteria to determine the appropriate level of care for all planned procedures.
Effective January 1, 2026, site of service is reviewed for advanced imaging services under Carelon Medical Benefits Management's Site of Care for Advanced Imaging criteria, and hospital outpatient site of care is considered medically necessary when ancillary services are required and not available at freestanding centers in the same geographic area. Effective November 7, 2025, bariatric surgery reoperation for inadequate weight loss is considered medically necessary if the original procedure fails, such as unsuccessful band adjustments, resulting in less than 50% excess weight loss or less than 20% total weight loss. Effective November 7, 2025, select surgical procedures previously reviewed for site of service in the inpatient setting are reviewed for site of service in the ambulatory surgical center setting under policy 11.01.525.
Independence Blue Cross Medicare Advantage updated medical policy MA08.142f effective 10/26/2026 to add combination therapy restrictions and neurologist consultation requirements for efgartigimod alfa-fcab (Vyvgart) and efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo). The policy now prohibits concurrent use with other FcRn blockers, complement inhibitors, or immune globulin, and requires neurologist involvement. Additionally, the policy removed prior anti-AChR antibody positivity as a coverage criterion for gMG treatment.
Independence Blue Cross updated Medical Policy 08.01.84f effective 10/26/2026 to add specific combination therapy restrictions for Vyvgart (efgartigimod alfa-fcab) and require neurologist involvement for gMG treatment. The policy now explicitly prohibits concurrent use with other FcRn blockers, complement inhibitors, or immune globulin, and mandates clinical outcomes monitoring through Evio for all covered cases.
Independence Blue Cross removed the anti-acetylcholine receptor (AChR) antibody-positive requirement for Vyvgart coverage in generalized myasthenia gravis, expanding eligibility. New restrictions added prohibit concurrent use with other FcRn blockers, complement inhibitors, IVIG, and require neurologist involvement. These changes take effect 10/26/2026.
Arkansas Blue Cross updated coverage criteria for several medications effective 2/1/2026, including archiving Beremagene Geperpavec-svdt and moving it to self-administered medication policy, expanding Pertuzumab coverage to include age 18+ patients and new off-label indications, updating maximum dosage quantities for medical benefit drugs, and adding two new policies for advanced Parkinson's disease and multiple myeloma treatments.
Independence Blue Cross updated MA08.142e to add specific dosing and frequency information for efgartigimod alfa-fcab (Vyvgart) and efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo), and removed all ICD-10 diagnosis codes from the policy. Billing teams must now report the most appropriate diagnosis code based on medically necessary criteria (generalized myasthenia gravis or CIDP) rather than relying on a predefined code list.
Independence Blue Cross updated policy 08.01.84e effective January 1, 2026, to remove coverage for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) under medical benefits due to its availability as a self-administered drug, now covered under the Self-Administered Drugs Policy 08.00.78. Coverage for intravenous Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis remains active with specified dosing (10 mg/kg weekly for 4 weeks, max 1200 mg per infusion for patients ≥120 kg) and clinical outcome monitoring requirements through Evio.
Florida Blue Medicare updated its Part B Step Therapy program effective July 15, 2025, removing Erythropoiesis Stimulating Agents from step therapy requirements and adding new non-preferred drugs in Cancer/Supportive Therapy, Complement Inhibitors, and Ophthalmic Agents categories that will require step therapy through preferred alternatives first.
BlueCross BlueShield of Tennessee and BlueCare Plus Tennessee publish the Commercial & BlueCare PASD Step Therapy Requirements guide for provider administered specialty medications. The guide says the listed medications need step therapy, that the medication must be a provider administered specialty drug used for a medically accepted indication, and that dose, frequency and duration may not exceed the safety and efficacy data supporting that indication. The source does not state an effective date or describe what changed.
Aetna requires precertification for efgartigimod alfa-fcab (Vyvgart) and efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) for all participating providers and members in applicable plan designs. The criteria below apply to commercial medical plans. Aetna considers Vyvgart or Vyvgart Hytrulo medically necessary for generalized myasthenia gravis (gMG) when the initial criteria are met, and considers Vyvgart Hytrulo medically necessary for chronic inflammatory demyelinating polyneuropathy (CIDP) when its criteria are met. Aetna considers pemphigus vulgaris and pemphigus foliaceus experimental, investigational, or unproven, and considers all other indications experimental, investigational, or unproven. Vyvgart is given as an intravenous infusion by a healthcare professional only. Vyvgart Hytrulo is given as a subcutaneous injection.
Rystiggo (rozanolixizumab-noli) may be considered medically necessary for generalized myasthenia gravis in adults 18 or older who are anti-AChR or anti-MuSK antibody positive, with an MG-ADL total score of 6 or more and documented inadequate response or intolerance to conventional therapy. Vyvgart, Vyvgart Hytrulo, and Imaavy (nipocalimab-aahu) are considered not medically necessary because other formulary alternatives are covered by the plan for those indications. The 06/15/2026 update removed the brand names Soliris and Ultomiris from the policy statements.
BCBSMS's neonatal Fc receptor blockers policy requires prior authorization, and the use of samples is not considered current or stable therapy. Rystiggo (rozanolixizumab-noli) may be considered medically necessary for generalized myasthenia gravis when the listed criteria are met. Vyvgart, Vyvgart Hytrulo and Imaavy (nipocalimab-aahu) are considered not medically necessary because other formulary alternatives are covered by the Plan, and the 06/15/2026 policy history entry removed the brand names Soliris and Ultomiris from the policy section.
Blue Cross and Blue Shield of Louisiana added HCPCS codes A9596, A9601, C9094, C9095, C9096, C9097, J0739, J1306, J1551, J2356, J2779, J2998, J3299, J9331, J9332, Q4259, Q4260 and Q4261 to its claims system effective July 1, 2022. For dates of service on and after August 15, 2022, the COVID-19 treatment bebtelovimab is reimbursed when billed with Modifier UC, which identifies the medication as commercially purchased, and the same administration codes are used for commercially purchased and government-supplied medication. Updated professional allowable charges for flu vaccination codes take effect for dates of service on and after November 1, 2022, and the new charges can be viewed in the Professional Provider Allowable Charges Search tool in iLinkBlue. FEP requires prior authorization for admission to residential treatment centers, and an administrative denial results if prior authorization is not obtained or the member is not enrolled in New Directions care management.
Watch J9332
Get one email when a payer policy names J9332, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J9332
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J9332 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.